Ultima-Tirzepatide

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GIP/GLP-1 RA

Introducing tirzepatide, a groundbreaking synthetic peptide designed to effectively manage blood sugar levels. This innovative treatment promotes insulin secretion during both the initial and subsequent phases while simultaneously lowering glucagon levels, all in response to fluctuating glucose levels.

Tirzepatide not only slows gastric emptying but also significantly reduces both fasting and post-meal glucose levels, curbing appetite and facilitating weight loss for individuals with type 2 diabetes. Additionally, it enhances insulin sensitivity, making it a versatile tool in diabetes management.

This powerful drug is linked to a C20 fatty diacid via a hydrophilic connector at the lysine position 20, resulting in robust binding to albumin in the bloodstream, which extends its half-life to an impressive 5 days.

GLP-1 (glucagon-like peptide-1) receptors (GLP-1R) are strategically located in key areas of the body, such as pancreatic beta cells and the gastrointestinal tract, playing a vital role in type 2 diabetes development. GLP-1R signaling is essential for blood sugar regulation, increasing insulin secretion in response to glucose, delaying gastric emptying, lowering glucagon levels, and promoting weight loss through appetite-suppressing pathways in the brain. Alongside GLP-1, glucose-dependent insulinotropic polypeptide (GIP) is a critical hormone that aids in glucose regulation by stimulating insulin secretion from pancreatic beta cells, with GIP being the dominant incretin hormone following meals.

While the exact mechanism of tirzepatide remains a subject of ongoing research, its unique ability to activate both GIP and GLP-1 receptors likely plays a significant role in its effectiveness for blood sugar and weight management. Studies indicate that the combination of GIP with a GLP-1R agonist elicits a stronger insulin response and greater suppression of glucagon than either hormone alone. Tirzepatide binds with high affinity to both GIP and GLP-1R, showing comparable binding affinity to GIP receptors as native GIP, while its GLP-1R affinity is five times lower than that of native GLP-1. This remarkable compound effectively activates GLP-1R signaling to promote glucose-dependent insulin secretion, utilizing either the GIP receptor (GIPR) or the GLP-1R. However, further research is needed to fully understand the role of GIPR activation in tirzepatide?s mechanism, as findings regarding its effects on blood sugar and weight management in clinical and preclinical studies have shown variability.